Initiator Pharma A/S, a clinical-stage pharma company, announced today the appointment of Christina Guldberg as Senior Director, Clinical Development and Outcomes Research (Rare Diseases), a new position designed to strengthen the company’s clinical development and Orphan drug capabilities. Christina Guldberg will assume her position on March 1.
Christina Guldberg comes from the position as Director Clinical Outcomes at Orphazyme A/S which she has held since 2017. She has a vast pharma experience in drug development and clinical development with a focus on rare diseases including companies like uniQure, Zealand Pharma, Novo Nordisk and Ferring Pharmaceuticals.
“With three programs in clinical development, Christina will be an important addition to our clinical development team. Her experience in drug and clinical development, patient centricity, outcomes research and relevant market access perspective is quite unique and will be key in our efforts to strengthen Initiator Pharma’s rare disease profile, with the IPTN2021 neuropathic pain program targeting trigeminal neuralgia in focus. Christina will also play a key role in our work to position our candidate drugs with the optimal possible choice of parameters and endpoints in order to prepare for upcoming reviews by the regulatory authorities as well as discussions with payers", says Initiator Pharma's CEO Claus Elsborg Olesen.
“In my previous positions I have generated a solid knowledge of the various aspects of drug development – from early-stage development to market access, including the need for regulatory and payer strategies and interactions. I am impressed by Initiator Pharma’s scientific approach and clinical programs, and I am really looking forward to join the company and contribute to the continued development efforts", says Christina Guldberg.